All 2 tracked stories fall under one category: health-it. DataMEDS AI, Inc. is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about EinsteinRx
All 2 tracked stories fall under one category: health-it. DataMEDS AI, Inc. is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.3 in the same window. This profile follows 2 Healthcare stories mentioning EinsteinRx across the period from August 12, 2026 to August 13, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 58 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering EinsteinRx. Shared-story counts are live from our verified record — not editorial picks.
DataMeds AI (NASDAQ:MEDS) is separating its pharmacy operations under a newly named Corexa Health division, with Corexa Pharmacy and Corexa Tech & Hub as subsidiaries. The move lays groundwork for vertical integration across pharmacy, telemedicine, and diagnostic lab services.
Health IT firm DataMeds AI uses its EinsteinRx AI and PharmacyChain blockchain platforms to power a direct-to-consumer pharmacy launch of Long COVID supplements, with a market projected to reach $32.8B. A pending acquisition of the product maker adds vertical integration.